Treatment of Multiple Myeloma: Best Practices from Levine Cancer Institute and Satellites

A panel of experts on multiple myeloma discuss the decision to refer patients with newly diagnosed multiple myeloma for transplant.

A detailed overview of therapeutic options for patients undergoing treatment for newly diagnosed multiple myeloma.

Key opinion leaders in the field of multiple myeloma review data looking at patient outcomes in the GRIFFIN and MASTER trials based on cytogenetic abnormalities.

The expert panel discusses factors that influence referral to transplant as well as selecting maintenance and consolidation therapies for patients with multiple myeloma.

Clinical insights on treatment options and strategies for patients with multiple myeloma who are not eligible for transplant.

Expert perspectives on assessing frailty for patients with multiple myeloma and its effect on treatment decisions.

A panel of experts discuss treatment and CAR T-cell therapy options for patients with relapsed/refractory disease who have limited treatment choices.

A comprehensive overview of emerging data from the KarMMa-3 and CARTITUDE-4 studies on CAR T-cell therapy in relapsed/refractory multiple myeloma.

The panel discusses how the emergence of CAR T-cell therapy has changed clinical care for patients with multiple myeloma.

Specialists in the field of multiple myeloma discuss bispecific antibodies, with a focus on the MajesTEC-1 study on teclistamab.

Continuing discussion on bispecific antibodies, attention turns to talquetamab and the MonumenTAL-1 clinical trial for patients with relapsed/refractory multiple myeloma.

An overview of the RedirecTT-1 study investigating teclistamab plus talquetamab in patients with relapsed/refractory multiple myeloma.

The expert panel presents the patient case of a 70-year-old man with multiple myeloma and discusses treatment decisions.

Shared insights on the patient profile of a 75-year-old woman with multiple myeloma with confirmed lytic disease.

The panel presents the case of a 68-year-old man with multiple myeloma and offers their initial impressions.

Concluding their comprehensive discussion on treating patients with multiple myeloma, the expert panel discusses unmet needs and looks to the future of treatment.

Experts in the field of multiple myeloma gathered to discuss treatment options, including bispecific antibodies, CAR T-cell therapy, and current and future FDA approvals for treatments.